160 related articles for article (PubMed ID: 19798026)
1. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
Savic S; McDermott MF
Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
[No Abstract] [Full Text] [Related]
2. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
3. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept and canakinumab.
Dubois EA; Rissmann R; Cohen AF
Br J Clin Pharmacol; 2011 May; 71(5):639-41. PubMed ID: 21375570
[No Abstract] [Full Text] [Related]
5. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
Curran MP
BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
[TBL] [Abstract][Full Text] [Related]
7. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
[TBL] [Abstract][Full Text] [Related]
9. [Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].
Carné X
Med Clin (Barc); 2011 Jan; 136 Suppl 1():34-7. PubMed ID: 21596185
[TBL] [Abstract][Full Text] [Related]
10. Corneal response to canakinumab in cryopyrin associated periodic fever syndrome.
Tsatsos M; Hawkin PN; Hossain P
Br J Ophthalmol; 2013 Aug; 97(8):1081-2. PubMed ID: 23740963
[No Abstract] [Full Text] [Related]
11. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
12. Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome.
Egawa M; Imai K; Mori M; Miyasaka N; Kubota T
J Clin Immunol; 2017 May; 37(4):339-341. PubMed ID: 28386702
[No Abstract] [Full Text] [Related]
13. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
14. Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab.
Mueller SM; Itin P; Haeusermann P
Skinmed; 2013; 11(2):80-3. PubMed ID: 23745225
[No Abstract] [Full Text] [Related]
15. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
[TBL] [Abstract][Full Text] [Related]
17. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
[TBL] [Abstract][Full Text] [Related]
18. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
20. Canakinumab in pediatric rheumatic diseases.
Wulffraat NM; Woo P
Expert Opin Biol Ther; 2013 Apr; 13(4):615-22. PubMed ID: 23451862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
